Бевацизумаб при метастатическом и рецидивирующем раке молочной железы: метаанализ рандомизированных исследований

1. Mariani G. New developments in the treatment of metastatic breast cancer: from chemotherapy to biological therapy. Ann Oncol 2005; 16 (suppl. 2): ii191–4.
2. Weidner N, Folkman J, Pozza F et al. Tumor angiogenesis: a new significant and independent prognostic indicator in earlystage breast carcinoma. J Natl Cancer Inst 1992; 84: 1875–87.
3. Uzzan B, Nicolas P, Cucherat M, Perret GY. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and metaanalysis. Cancer Res 2004; 64 (9): 2941–55.
4. McLeskey SW, Tobias CA, Vezza PR et al. Tumor growth of FGF or VEGF transfected MCF-7 breast carcinoma cells correlates with density of specific microvessels independent of the transfected angiogenic factor. Am J Pathol 1998; 153 (6): 1993–2006.
5. Linderholm B, Grankvist K, Wilking N et al. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J Clin Oncol 2000; 18 (7): 1423–31.
6. Ferrara N. Role of vascular endothelial growth factor in the regulation of angiogenesis Kidney Int 1999; 56: 794–814.
7. Gaspanni G. Angiogenesis in breast cancer role in biology, tumor progression, and prognosis. In: Bowcock A (Ed.). Breast Cancer Molecular Genetics, Pathogenesis, and prognosis. Humana Press, Inc, NJ, 1999; 34–371.
8. Kerbel RS. Tumor Angiogenesis. N Engl J Med 2008; 358: 2039–49.
9. Cross MJ, Dixelius J, Matsumoto T, Claesson-Welsh L. VEGF-receptor signal transducnon TrendsBwinem Sit 2003; 28: 488–94.
10. Foekens JA, Peters HA, Grebenchtchikov N et al. High tumor levels of vascular endothehal growth factor predict poor response to systemic therapy in advanced breast cancer. Camer Res 2001; 61: 5407–14.
11. Linderholm B, Tavelin B, Grankvist K, Hennksson R. Vascular endothehal growth factor is of high prognostic value in node-negative breast carcinoma. Clin Omol 1998; 16: 3121–8.
12. Linderholm B, Grankvist K, Wilkmg N et al. Correlation of vascular endothehal growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. Clin Oncol 2000; 18: 1423–31.
13. Scott LJ. Bevacizumab: in first-line treatment of metastatic breast cancer. Drugs 2007; 67 (12): 1793–9.
14. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothehal growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593–9.
15. Kim KJ, Li B, Houck K et al. The vascular endothehal growth factor proteins identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7: 53–64.
16. Cobleigh MA, Langmuir VK, Sledge GW et al. A Phase I/II dose-escalation trial of bevacizumab in prev lously treated metastatlc breast cancer. Semin Otuol 2003; 30: 117–24.
17. Miller KD, Chap LI, Holmes FA et al. Randomized Phase 111 trial of capecitabme compared wirh bevacizumab plus capecitabme in patients with previously treated metastatlc breast cancer. Clin Oncol 2005; 23: 792–9.
18. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for merastanc breast cancer. N Engl J Med 2007; 357: 2666–76.
19. Miles D, Investigators A. A randomized, double-blind study of bevacizumab in combination with docetaxel as first-line treatment of patients with HER2-negaiive locally recurrent or metastatic breast cancer efficacy and safety. J Clin Oncol 2008; 26: LBA1011.
20. Burstem H, Parker L, Savoie J. Phase II trial of the anti-VEGF antibody bevacizumab in combination with vinorelbine for refractory advanced breast cancer. Breast Cancer Res Treat 2002; 76.
21. Burstem H, Spigel D, Kmdsvogel K et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer a randomized Phase II study. Breatt Cancer Res Treat 2005; 94 (Suppl. 1): S6.
22. O'Shaughnessy JA, Brufsky A: RiBBON 1 and RiBBON2 Phase III Trials of bevacizumab with standard chemotherapy for metastatic breast cancer. Clin Breast Cancer 2008; 8: 370–3.
23. Robert NJ, Glaspy J, Brufsky A et al. RIBBON-1 randomized, double-blind, placebo-controlled. Phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009; 27 (Suppl. 15): S15.
24. Miller K, Wang D, Gralow J et al. Paclitaxel plus bevacizumab versus paclitacel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666–76.
25. Pivot X, Verma S, Thomssen C et al. Clinical benefit of bevacizumab plus first-line docetaxel in elderly patients with locally recurrent or Metastatic breast cancer. J Clin Oncol 2009; 27: 15s (abstr 1094).
26. Robert NJ, Dieras V, Glaspy J et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer. J Clin Oncol 2009; 27: 15s (abstr 1005).
27. Miller KD, Chap LI, Holmes FA et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23 (4): 792–9.
28. Burstein HJ, Spigel D, Kindsvogel K et al. Metronomic chemotherapy with and without bevacizumab for advanced breast cancer: a randomized phase II study. Breast Cancer Res Treat 2005; 94 (Suppl. 1): S6.
29. Daniele G, Marciano R, Tortora G. The role of bevacizumab in breast cancer. Eur J Cancer Suppl 2008; 6: 26–9.
30. Yoshiji H, Harris SR, Thorgeirsson UP. Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997; 57 (18): 3924–8.
31. Relf M, LeJeune S, Scott PA et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor b-1, platelet-derived endothelial cell growth factor, placenta growth factor and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res 1997; 57: 963–9.
32. Morales DE, McGowan KA, Grant DS et al. Estrogen promotes angiogemc activity in human umbilical vein endothehal cells in vitro and in a munne model. Circulation 1995; 91: 755–63.
33. Losordo DW. Isner JM. Estrogen and angiogenesis a review. Artcrioscier Thromb Vase Biol 2001; 21: 6–12.
34. Kazi AA, Jones JM, Koos RD. Chromatm immunoprecipitation analysis of gene expression in the rat uterus in vino estrogen-induced recruitment of both estrogen receptor a and hypoxia-mduuble factor 1 to the vascular endothehal growth factor promoter. Mol Endocrinol 2005; 19: 2006–19.
35. Albrecht ED, Aberdeen GW, Niklaus AL et al. Acute temporal regulation of vascular endothehal growth/permeability factor expression and endothehal morphology in the baboon endometnum by ovarian steroids. J Clin Endoirmol Metab 2003; 88: 2844–52.
36. Takei H, Lee ES, Jordan VC. In vitro regulation of vascular endothehal growth factor by estrogens and annestrogens in estrogen-receptor positive breast cancer. Breast Canter 2002; 9: 39–42.
37. Nakamura J, Savinov A, Lu Q, Brodie A. Estrogen regulates vascular endothehal growth/permeability factor expression in 7,12-dimethylbenz(a)anthracene-mduced rat mammary tumors. Endocrinology 1996; 137: 5589–96.
38. Jam RK, Safabakhsh N, Sckell A et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor role of vascular endothehal growth factor. Proc Natl Acad Sci. USA 95, 1998; 10820–5.
39. Manders P, Beex LV, Tjan-Heijnen VC et al. Vascular endothehal growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma. Cancer 2003; 98: 2125–32.
40. Traina T, Dickler M, Caravelli J et al. A Phase II trial of leirozole in combination with bevacizumab, an anti-VEGF antibody, in patients with hotmone receptor-positive metastatic breast cancer Presented at 28th Annual San Antonio Breast Cancer Symposium 2005. San Antonio, TX, USA, 8–11 December 2005.
41. Trama T, Dickler M, Caravelli J et al. A feasibility study of an aromatase inhibitor, letrozole, and the antibody to vascular endothehal growth factor (VEGF), bevacizumab, in patients with hormone receptor-positive metastatic breast cancer. Prat Am Soc Clm Oncol 2005; 23: S76.
42. Trama TA, Rugo HS, Caravelli JF et al. Feasibility trial of letrozole in combination with bevacizumab in patients with metastatic breast cancer. J Clin Oncol 2009; DOI 0 JCO200921.8784vl.
43. Yardley D, Peacock N, Arrowsmith E et al. Preliminary safety results from a multicenter Phase 2 non-comparative two arm pilot of bevacizumab with anastrozole or fulvestrant as first-line metastatic breast cancer therapy. Cancer Res 2009; 69 (Suppl. 2): S2.
44. Pegram MD, Reese DM. Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothehal growth factor. Semin Oncol 2002; 29: 29–37.
45. Linderholm B, Andersson J, Lmdh B et al. Overexpression of c-erbB-2 is related to a higher expression of vascular endothehal growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment. Eur I Cancer 2004; 40 (1): 33–4.
46. Epstein M, Ayala R, Tchekmedyian N et al. HER2-overexpressmg human breast Cancer xenografts exhibit increased angiogenic potential mediated by vascular endothelial growth factor (VKGF). Breast Cancer Res Treat 2002; 76: S143.
47. Stewart LA, Parmar MKB. Meta-analysis of the literature or of individual patient data: Is there a difference? Lancet 1993; 341: 418–22.
48. Dickler M, Stopeck A, Ma W et al. Final results from a Phase II evaluation of lapatmib and bevacizumab in HER2-overexpressing metastatic breast cancer Presented at 31a Annual San Antonio Breast Cancer Symposium 2008. San Antonio, TX, USA, 10–14 December 2008.

И.В.Колядина, И.В.Поддубная

Кафедра онкологии ГОУ ДПО РМАПО, Москва